Ivax Glucophage XR Launch Halted By Purepac Exclusivity Suit
Executive Summary
Purepac's lawsuit over FDA's 180-day exclusivity determination on generic metformin extended-release challenges the agency's interpretation of first-to-file rights for amended ANDAs
You may also be interested in...
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
Purepac Glucophage XR ANDA Status Could Factor Into Injunction Ruling
A D.C. federal judge's decision on whether Ivax should be preliminarily enjoined from immediately marketing its generic version of Glucophage XR could hinge on the imminent approvability of Purepac's ANDA for metformin extended-release